DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for lymphatic system disease — screening already-approved drugs against its 42-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleLymphatic system disease maps to a 42-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for lymphatic system disease is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
ABO, alpha 1-3-N-acetylgalactosaminyltransferase and alpha 1-3-galactosyltransferase (ABO) — ABO is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet 6-deoxy-alpha-l-galactopyranosyldrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 4Y63 · 1.3 Å · ligand octyl 2-O-(6-deoxy-alpha-L-galactopyranosyl)-beta-D-galactopyranoside (BHE). Experimental structure, not a prediction.
What the evidence adds up to
A 2015 case report of a 35-year-old woman with whole-body lymphangiomatosis, diagnosed at two months of age and with progressive disease, used near-infrared fluorescence lymphatic imaging. The imaging showed that her peripheral lymphatics in the extremities appeared largely normal compared to prior studies, but tortuous lymphatic vessels, drainage from peripheral lymphatics into lymphangiomas, and extensive dermal lymphatics were observed in the left thigh and inguinal regions where she had had previous surgical assaults. The authors concluded that further research into anatomical and functional lymphatic changes associated with the progression and treatment of lymphangiomatosis could aid in understanding the pathophysiology and point to treatment strategies.
A 2024 review assessed the potential of lymphatic-targeted drug delivery systems, focusing on tumour therapy and vaccination. It noted that nanotechnologies and innovative biomaterials have facilitated the development of lymphatic-targeted drug carriers, leveraging endogenous macromolecules to enhance drug delivery efficiency. Systems such as liposomes, micelles, inorganic nanomaterials, hydrogels, and nano-capsules were described as demonstrating significant potential for delivering drugs to the lymphatic system. The review concluded that understanding the physiological functions of the lymphatic system and its involvement in diseases underscores the promise of targeted drug delivery in improving treatment outcomes.
A 2021 review of primary lymphedema, a chronic condition of tissue lymph retention and swelling, stated that lymphatic dysfunction can affect immune function, influence cancer development and spread, and determine fat transport. It noted that genetic studies and imaging techniques have enabled recognition of primary lymphedema as a heterogeneous condition in terms of genetic causes and disease mechanisms. A 2004 article discussed manual lymphatic drainage therapy as a complementary therapy, identifying its value and indications, but provided no trial data on efficacy. A 2011 historical perspective reviewed the evolution and discovery of the lymphatic system, noting its clinical importance concerning cancer, edema, surgery, and the immune response.
No drug is mentioned in any of these abstracts. No survival or response rates are given. What is missing for any drug-repurposing approach to lymphatic system disease is evidence from controlled clinical trials testing a specific compound, adequate funding for such trials, and patient stratification based on the genetic heterogeneity now recognised in conditions like primary lymphedema.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Clinical Anatomy · 2011 · 58 citations
The lymphatic system: A historical perspective
AbstractThe study of the lymphatic system has a lengthy history, with many notable medical minds making important contributions. We now appreciate that this system is an essential component of the immune system, as well as vital to the maintenance of fluid homeostasis within the body. A good knowledge of the lymphatic system is clinically important concerning cancer, edema, surgery, and the immune response. This article reviews the history of the evolution and discovery of the lymphatic system.
Development and physiological functions of the lymphatic system: insights from human genetic studies of primary lymphedema
AbstractPrimary lymphedema is a long-term (chronic) condition characterized by tissue lymph retention and swelling that can affect any part of the body, although it usually develops in the arms or legs. Due to the relevant contribution of the lymphatic system to human physiology, while this review mainly focuses on the clinical and physiological aspects related to the regulation of fluid homeostasis and edema, clinicians need to know that the impact of lymphatic dysfunction with a genetic origin can be wide ranging. Lymphatic dysfunction can affect immune function so leading to infection; it can influence cancer development and spread, and it can determine fat transport so impacting on nutrition and obesity. Genetic studies and the development of imaging techniques for the assessment of lymphatic function have enabled the recognition of primary lymphedema as a heterogenic condition in terms of genetic causes and disease mechanisms. In this review, the known biological functions of several genes crucial to the development and function of the lymphatic system are used as a basis for understanding normal lymphatic biology. The disease conditions originating from mutations in these genes are discussed together with a detailed clinical description of the phenotype and the up-to-date knowledge in terms of disease mechanisms acquired from in vitro and in vivo research models.
Home Health Care Management & Practice · 2004 · 27 citations
Manual Lymphatic Drainage Therapy
AbstractHealth care providers are constantly confronted with the challenge of providing quality health care while at the same time containing escalating costs. Incorporating complementary therapies into standard health care practices can assist in escalating the healing process, enhancing general wellness, focusing on prevention, and promoting a better quality of life. This article discusses manual lymphatic drainage therapy and identifies the value of as well the indications for the therapy. A brief overview of the lymphatic system is included.
Lymphatic Research and Biology · 2015 · 10 citations · open access
Near-Infrared Fluorescence Lymphatic Imaging in Lymphangiomatosis
AbstractBACKGROUND: Lymphangiomatosis is a rare disorder of the lymphatic system that can impact the dermis, soft tissue, bone, and viscera and can be characterized by lymphangiomas, swelling, and chylous discharge. Whether disordered lymphangiogenesis in lymphangiomatosis affects the function and anatomy of the entire systemic lymphatic circulation or is localized to specific sites is not fully known. METHODS AND RESULTS: A 35-year-old Caucasian female diagnosed with whole-body lymphangiomatosis at 2 months of age and who continues to present with progressive disease was imaged with near-infrared fluorescence lymphatic imaging. While the peripheral lymphatics in the extremities appeared largely normal compared to prior studies, we observed tortuous lymphatic vessels, fluorescence drainage from the peripheral lymphatics into lymphangiomas, and extensive dermal lymphatics in the left thigh and inguinal regions where the subject had previously had surgical assaults, potentially indicating defective systemic lymphangiogenesis. CONCLUSIONS: Further research into anatomical and functional lymphatic changes associated with the progression and treatment of lymphangiomatosis could aid in understanding the pathophysiology of the disease as well as point to treatment strategies.
State-of-the-art drug delivery system to target the lymphatics
AbstractPRIMARY OBJECTIVE: The primary objective of the review is to assess the potential of lymphatic-targeted drug delivery systems, with a particular emphasis on their role in tumour therapy and vaccination efficacy. REASON FOR LYMPHATIC TARGETING: The lymphatic system's crucial functions in maintaining bodily equilibrium, regulating metabolism, and orchestrating immune responses make it an ideal target for drug delivery. Lymph nodes, being primary sites for tumour metastasis, underscore the importance of targeting the lymphatic system for effective treatment. OUTCOME: Nanotechnologies and innovative biomaterials have facilitated the development of lymphatic-targeted drug carriers, leveraging endogenous macromolecules to enhance drug delivery efficiency. Various systems such as liposomes, micelles, inorganic nanomaterials, hydrogels, and nano-capsules demonstrate significant potential for delivering drugs to the lymphatic system. CONCLUSION: Understanding the physiological functions of the lymphatic system and its involvement in diseases underscores the promise of targeted drug delivery in improving treatment outcomes. The strategic targeting of the lymphatic system presents opportunities to enhance patient prognosis and advance therapeutic interventions across various medical contexts, indicating the importance of ongoing research and development in this area.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
